![Mark Fraga](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Mark Fraga worked as Vice President-Marketing at Flexion Therapeutics, Inc. from 2016 to 2017.
Prior to that, he was Head-Global Marketing at Sanofi Corp.
Mr. Fraga completed his undergraduate degree at the University of Pennsylvania, his graduate degree at the University of Oxford, and his MBA at The Wharton School of the University of Pennsylvania.
Ehemalige bekannte Positionen von Mark Fraga
| Unternehmen | Position | Ende |
|---|---|---|
| FLEXION THERAPEUTICS, INC. | Vertrieb & Marketing | 01.05.2017 |
Sanofi Corp.
 Sanofi Corp. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi Corp. is a biopharmaceutical company dedicated to improving health outcomes through innovative medicines, vaccines, and patient-centered care. The company is based in Bridgewater, NJ. The company offers a broad portfolio including prescription medicines across therapeutic areas such as immunology, neurology, oncology, rare diseases, cardiovascular disease, diabetes, and transplant, alongside an extensive range of vaccines protecting against infectious diseases like influenza, respiratory syncytial virus (RSV), dengue, and COVID-19. Sanofi emphasizes scientific innovation with a robust R&D pipeline comprising clinical-stage projects, including advanced therapies like bispecific antibodies, gene therapies, and mRNA vaccines. The company addresses complex conditions such as chronic graft-versus-host disease in transplant patients and rare blood disorders like immune thrombocytopenia purpura, having launched therapies in these areas. Sanofi collaborates with healthcare professionals, patient communities, advocacy groups, and governments to expand access, promote holistic care, and advance science. Social impact initiatives focus on health equity, inclusion, environmental factors affecting respiratory health, and responsible business practices. Sanofi provides resources for healthcare providers and patients, including prescribing information, patient support, and educational materials, and maintains transparent communication through media channels and regular updates on financial performance, regulatory approvals, and clinical trial progress. | Corporate Officer/Principal | - |
Ausbildung von Mark Fraga
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
10
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with musculoskeletal conditions | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi Corp.
Sanofi Corp. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi Corp. is a biopharmaceutical company dedicated to improving health outcomes through innovative medicines, vaccines, and patient-centered care. The company is based in Bridgewater, NJ. The company offers a broad portfolio including prescription medicines across therapeutic areas such as immunology, neurology, oncology, rare diseases, cardiovascular disease, diabetes, and transplant, alongside an extensive range of vaccines protecting against infectious diseases like influenza, respiratory syncytial virus (RSV), dengue, and COVID-19. Sanofi emphasizes scientific innovation with a robust R&D pipeline comprising clinical-stage projects, including advanced therapies like bispecific antibodies, gene therapies, and mRNA vaccines. The company addresses complex conditions such as chronic graft-versus-host disease in transplant patients and rare blood disorders like immune thrombocytopenia purpura, having launched therapies in these areas. Sanofi collaborates with healthcare professionals, patient communities, advocacy groups, and governments to expand access, promote holistic care, and advance science. Social impact initiatives focus on health equity, inclusion, environmental factors affecting respiratory health, and responsible business practices. Sanofi provides resources for healthcare providers and patients, including prescribing information, patient support, and educational materials, and maintains transparent communication through media channels and regular updates on financial performance, regulatory approvals, and clinical trial progress. | Health Technology |
